Septerna (NASDAQ:SEPN) Downgraded by Wall Street Zen to Sell

Septerna (NASDAQ:SEPN) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Several other equities analysts have also weighed in on the stock. Cantor Fitzgerald raised their price objective on shares of Septerna from $20.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, May 16th. Wells Fargo & Company raised their target price on shares of Septerna from $11.00 to $18.00 and gave the stock an “equal weight” rating in a report on Friday, May 16th. Finally, HC Wainwright started coverage on shares of Septerna in a report on Monday, June 23rd. They issued a “buy” rating and a $26.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $26.75.

Septerna Trading Up 0.3%

NASDAQ:SEPN opened at $11.72 on Friday. Septerna has a twelve month low of $4.17 and a twelve month high of $28.99. The company has a 50-day moving average of $11.52 and a 200-day moving average of $9.21. The firm has a market cap of $522.48 million and a price-to-earnings ratio of -1.16.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.51). Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $22.50 million. On average, research analysts forecast that Septerna will post -7.11 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SEPN. Tower Research Capital LLC TRC purchased a new stake in shares of Septerna in the fourth quarter worth approximately $25,000. Legal & General Group Plc purchased a new stake in shares of Septerna in the fourth quarter worth approximately $42,000. Summit Investment Advisors Inc. purchased a new stake in shares of Septerna in the fourth quarter worth approximately $45,000. BNP Paribas Financial Markets purchased a new stake in shares of Septerna in the fourth quarter worth approximately $52,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Septerna in the first quarter worth approximately $49,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.